Recro Pharma

Societal CDMO, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief.   It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy

Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs

Recro Appoints Laura L. Parks, Ph.D.

Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboarding European CTS Customers Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboarding European CTS Customers

Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings

Underwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million

Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the pricing of its public offering of 13,333,333 shares of its common stock at a price to the public of $2.25 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million. In addition, Recro has granted the underwriters a 30-day option to purchase up to 1,999,999 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 14, 2021, subject to satisfaction of customary closing conditions.

Recro Announces Pricing of $30.0 Million Public Offering of Common Stock

EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the public offering will be sold by Recro.  Recro is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Recro Announces Proposed Public Offering of Common Stock

Recro Pharma, Inc. (REPH) CEO David Enloe on Q1 2021 Results - Earnings Call Transcript

Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue

Recro Reports First Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time

Recro to Report Financial Results for First Quarter 2021 on May 6

Additional Contract Broadens and Further Strengthens Customer Product Portfolio Additional Contract Broadens and Further Strengthens Customer Product Portfolio

Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences

Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing

Recro Strengthens Business Development Team to Drive Customer Growth and Diversification

Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2020 Results - Earnings Call Transcript

Recro Reports Fourth Quarter and Year End 2020 Financial Results

Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26 Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26

Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced

Reductions in Debt Principal and Interest Rate Further Strengthen Balance Sheet, Support Ongoing Efforts to Best Position Company for Significant CDMO Business Growth Reductions in Debt Principal and Interest Rate Further Strengthen Balance Sheet, Support Ongoing Efforts to Best Position Company for Significant CDMO Business Growth

Recro Announces Amendment to Athyrium Credit Facility

Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time

Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26

MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that it granted an inducement award to its newly-appointed President and Chief Executive Officer, David Enloe.

Recro Grants Inducement Award to New Chief Executive Officer

Ashford Hospitality Trust

Farmer Bros.

Globus Maritime

Independence Contract Drilling

Just Energy Group

AG Mortgage Investment Trust

Perhaps this year like no other has demonstrated the yin-yang effect of the market. While we've seen incredible winners, these companies represent the worst performing stocks of 2020.

The 7 Worst Performing Stocks of 2020

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Recro Pharma (REPH) Stock?

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q3 2020 Results - Earnings Call Transcript

  Shares of Recro Pharma (NASDAQ:REPH) were unchanged after the company reported Q3 results.

Recap: Recro Pharma Q3 Earnings

Company Secures Three-Year Renewal of Licens e and Supply Agreement with Lannett , A Generic s Pharmaceutical Company, for Manufacturing of Verelan PM ® , Verelan SR ® and Verapamil PM

Recro Reports Third Quarter 2020 Financial Results

GAINESVILLE, Ga., Sept.  18, 2020  (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 4:10 p.m. ET.

Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

Launches Clinical Trial Materials Business and Secures New Customers

News for Recro Pharma Stock (REPH)